Targeting antigen-specific T cells by genetically engineered antigen presenting cells: A strategy for specific immunotherapy of autoimmune disease
Open Access
- 1 July 2000
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 106 (1-2) , 145-153
- https://doi.org/10.1016/s0165-5728(00)00201-0
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking PathwayJournal of Biological Chemistry, 1997
- Immunotherapy in neuromuscular disorders: Current and future strategiesMuscle & Nerve, 1996
- The Roles of Costimulation and Fas in T Cell Apoptosis and Peripheral ToleranceImmunity, 1996
- T-Helper Epitopes on Human Nicotinic Acetylcholine Receptor in Myasthenia GravisAnnals of the New York Academy of Sciences, 1993
- Autoimmune T cell recognition of human acetylcholine receptor: the sites of T cell recognition in myasthenia gravis on the extracellular part of the α subunitEuropean Journal of Immunology, 1990
- T-cell reactivity in myasthenia gravisJournal of Autoimmunity, 1989
- In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes.Journal of Clinical Investigation, 1988
- Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis.Journal of Clinical Investigation, 1988
- Myasthenia GravisNew England Journal of Medicine, 1977
- EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS: CELLULAR AND HUMORAL IMMUNE RESPONSES*Annals of the New York Academy of Sciences, 1976